Abstract 3898: CDA predicts life-threatening toxicities in AML patients treated with cytarabine

Raphaëlle Fanciullino(Inserm), Régis Costello(Inserm), L’Houcine Ouafik(Centre National de la Recherche Scientifique), Catherine Roche‐Lestienne(Inserm), Laure Farnault(Aix-Marseille Université), Mélanie Donnette(Inserm), Geoffroy Venton(Inserm), Joseph Ciccolini(Centre de Recherche en Cancérologie de Marseille), Bruno Lacarelle, Vadim Ivanov(Hôpital de la Conception), Yaël Berda‐Haddad(Assistance Publique Hôpitaux de Marseille)
Cancer Research
July 1, 2018
10.1158/1538-7445.am2018-3898
Cited by 0

Related Papers

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment
|Blood|2002|517
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
|New England Journal of Medicine|2010|385
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
|Blood|2021|157
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission
|Blood|2010|133